UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 21, 2004
Lifecore Biomedical, Inc.
(Exact name of Registrant as specified in its charter)| | | | | |
| Minnesota | | O-4136 | | 41-0948334 |
| |
| |
|
| (State or other jurisdiction of | | (Commission File Number) | | (IRS Employer Identification No.) |
| incorporation or organization) | | | | |
| | | | | |
| 3515 Lyman Boulevard | | | | |
| Chaska, Minnesota | | | | 55318 |
| | | |
|
| (Address of principal executive | | | | (Zip Code) |
| offices) | | | | |
Registrant’s telephone number, including area code: 952-368-4300
TABLE OF CONTENTS
Item 7. Financial Statements and Exhibits
| (c) | | The following exhibit is being furnished herewith: |
| | | |
| 99.1 | | Press release dated July 21, 2004 |
Item 9. Regulation FD Disclosure
On July 21, 2004 Lifecore Biomedical, Inc. (“Lifecore”) issued a press release which announced that it has signed an agreement with Advanced Medical Optics (AMO), an ophthalmic medical device company based in Santa Ana, California, to supply Lifecore’s hyaluronan-based viscoelastic under private label.
A copy of Lifecore’s press release is attached hereto as Exhibit (99.1) and hereby incorporated by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | LIFECORE BIOMEDICAL, INC.
| |
| Dated: July 22, 2004 | /s/ Dennis J. Allingham | |
| | Dennis J. Allingham | |
| | Chief Executive Officer and President | |
Exhibit Index
| | | |
| 99.1 | | Press release dated July 21, 2004 |
